Jasper Therapeutics receives Nasdaq delisting notice for equity shortfall

Jasper Therapeutics, Inc.

On Aug 21, 2026, Nasdaq notified Jasper it fails $2.5M stockholders' equity requirement under Rule 5550(b)(1).
Company has 45 days (until Oct 5, 2026) to submit a compliance plan to regain compliance.
Plans to seek stockholder approval to convert Non-Voting Convertible Preferred Stock to boost equity.
If plan accepted, Nasdaq may grant up to 180-day extension; otherwise hearing process available.
No immediate effect on listing; common stock continues trading on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.